Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Incyte (INCY) and Vertex Pharmaceuticals (VRTX). But which of these two stocks presents investors with the ...

Below is Validea's guru fundamental report for VERTEX PHARMACEUTICALS INC (VRTX). Of the 22 guru strategies we follow, VRTX rates highest using our P/B Growth Investor model based on the published ...

In the latest market close, Vertex Pharmaceuticals (VRTX) reached $409.56, with a -0.62% movement compared to the previous day. This change was narrower than the S&P 500's 1.54% loss on the day.

In a report released today, Joon Lee from Truist Financial maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report). The company’s shares closed last Friday at $409.56.

In a report released today, Mohit Bansal from Wells Fargo assigned a Buy rating to Vertex Pharmaceuticals (VRTX – Research Report), with a price target of $460.00. The company’s shares closed ...

Clinical trial disappointments and technical sell signals pressure VRTX, down 15% over six months. Get Real-Time News and Alerts for Your Portfolio This occurs when the 50-day moving average falls ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...